Letter

Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes

BMJ 2003; 327 doi: 10.1136/bmj.327.7407.164 (Published 17 July 2003)
Cite this as: BMJ 2003;327:164.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Edward A Nardell (enardell@pih.org), associate professor
  1. Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02115, USA

    EDITOR—In their decision analysis Sterling et al hypothesise but offer no evidence that the efficacy of DOTS (directly observed treatment, short course) has ever been diminished by DOTS-plus.1 On the contrary, under the current rigorous procedure for obtaining second line drugs at drastically reduced prices, the Green Light Committee of the World Health Organization assures that only programmes with demonstrably strong DOTS and DOTS-plus components are approved, …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular